Nagalakshmi S

Nagalakshmi S


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2024 in Journal of Advances in Medical and Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
SSSivaranjani. P. S
Sivaranjani. P. S
PSPriyadharshini. S
Priyadharshini. S
NSNagalakshmi S
Nagalakshmi S
Digital health technology is revolutionizing the healthcare landscape by leveraging digital and information technologies to enhance healthcare delivery, monitoring and management. This technology encompasses a wide range of tools, including mobile apps, wearable, telemedicine, electronic health records, and AI-driven diagnostics. Digital health technologies may be beneficial but also problematic. Development requires navigating complicated regulatory systems and meeting changing criteria. These technologies, particularly those using AI algorithms, need robust clinical validation to prove their safety and usefulness. Health data is delicate; thus, privacy and security are crucial. Successful adoption requires interoperability with current healthcare systems, seamless user experience, and ethical and legal considerations. To maximize digital health technology's potential, clinical evidence, financial management, and change resistance must be addressed. Addressing these issues requires collaboration between healthcare professionals, technology professionals, regulators, and patients. Digital health technology can empower people, enhance patient outcomes, and transform healthcare by balancing innovation and safety. Despite challenges, digital health technology improves global health, needing continuing innovation, regulatory compliance, and equal access. This review provides a comprehensive analysis of the US Food and Drug Administration (USFDA) regulations governing digital health technologies, including, classification of DHT, mobile health applications, wearables, Cyber security, Regulatory expectations and challenges.

15 January 2023 in Journal of Drug Delivery and Therapeutics
Verified
Journal Article
Open access
PDF file
NSNagalakshmi S
Nagalakshmi S
STSuthahar Teshini
Suthahar Teshini
ESE Shoba
E Shoba
SMShyam Madhavan
Shyam Madhavan
SSSuresh Shilpa
Suresh Shilpa
SSS. Sintinya
S. Sintinya
The recent advances in ocular drug delivery have been successful in surpassing conventional therapy, owing to its considerable limitations. This study aims to develop and optimize in-situ liposomal ocular system to design once-daily liquid preparation to treat Keratoconjunctivitis sicca. Liposomes of Hyaluronic acid were prepared using soya lecithin by a thin film hydration method. Eight trial formulations were made by keeping drug as fixed ratio and varying the concentration of cholesterol and soya lecithin. The optimized formulation was selected for the formulation of liposomal in-situ hydrogel. Optimization was carried out by Central Composite Design (CCD) studying the factors, amount of cholesterol and soya lecithin and its effects on the responses, % In- vitro drug release (R1) and Percent Entrapment Efficiency (% EE) (R2). The best predicted model for R1 was the Quadratic model and, for R2 was Two-Factor Interaction model (2FI) without any significant lack of fit. Optimum formulation was found to be at 1:1:4 (drug: cholesterol: soya lecithin) showed sustained drug release of 31.28% in 8 hours with highest %EE of 47.36%. Liposomal in-situ gel preparation retained better stability throughout the study period when stored at refrigerator temperature and displayed prolonged action (76.44%) when compared to liposomal formulation (68.72%). Keywords: Liposomes, Hyaluronic acid, Optimized formulation, CCD, sustained drug release, in-situ hydrogel.

25 June 2026 in Nursing Reports
Verified
Journal Article
Open access
PDF file
MKMinimole Kalarickal Kunjan
Minimole Kalarickal Kunjan
SASeethalakshmi Avudaiappan
Seethalakshmi Avudaiappan
ZAZechariah Jebakumar Arulanantham
Zechariah Jebakumar Arulanantham
NSNagalakshmi S
Nagalakshmi S
Background: Clinical reasoning is a vital competency for safe nursing practice, yet no validated Arabic instrument exists to assess this skill among nursing students in Saudi Arabia. Aim: This study aimed to translate, culturally adapt, and psychometrically evaluate the Arabic version of the Clinical Reasoning Scale (CRS) and to investigate clinical reasoning among Saudi nursing students. Methods: This methodological instrument validation study with a cross-sectional survey component was conducted in Saudi Arabia between January 2024 and May 2025 among nursing students. The Arabic Clinical Reasoning Scale (CRS-A) was translated and culturally adapted in accordance with the WHOQOL Group guidelines for instrument translation. Content validity was assessed by 10 experts, and construct validity was evaluated using exploratory factor analysis (n = 365). The response rate was 98.65%. Internal consistency was evaluated using Cronbach’s alpha (n = 365), and test–retest reliability (n = 30) was measured with the Intraclass Correlation Coefficient (ICC) over a two-week period. Descriptive statistics, one-way analysis of variance (ANOVA), and independent sample t-tests were also performed. Results: The tool’s content validity (S-CVI = 0.98) was confirmed by a panel of experts. The CRS-A demonstrated excellent temporal stability (ICC = 0.95, p < 0.001) and internal consistency (Cronbach’s α = 0.935). The exploratory factor analysis showed that the 16 items’ factor loadings ranged from 0.542 to 0.807, and three factors accounted for 64.33% of the total variance. Students self-reported agreement with clinical reasoning abilities (mean scores: 3.81–4.18). No significant differences in clinical reasoning were found by age (p = 0.102) or gender (p = 0.226), but significant differences were found by Cumulative Grade Point Average (CGPA) (p < 0.001). Conclusions: The Arabic Clinical Reasoning Scale demonstrated preliminary psychometric performance for measuring clinical reasoning among Arabic-speaking student nurses. It provides educators with a valuable tool for identifying learning needs and evaluating educational interventions.

14 July 2026 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SKSenthilraja Kaliyamoorthy
Senthilraja Kaliyamoorthy
RARajasekhar At
Rajasekhar At
AMArif Ansari Mohamed
Arif Ansari Mohamed
SSShafiq-Un-Nabi Sheikh
Shafiq-Un-Nabi Sheikh
ADAnusha D
Anusha D
NSNagalakshmi S
Nagalakshmi S

1 March 2026 in International Journal of Pharmacy and Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
PSPathipati Sunitha
Pathipati Sunitha
RSR. S. Sailesh
R. S. Sailesh
NSNagalakshmi S
Nagalakshmi S
Objective of this review was to evaluate the evolution, applications, and regulatory implications of artificial intelligence technologies in pharmaceutical regulatory affairs, with emphasis on their influence on drug development, regulatory submissions, and global harmonization. This review examines published literature, regulatory authority documents, and international reports describing the integration of artificial intelligence into regulatory processes. Key technological approaches, including machine learning, natural language processing, and automated workflow systems, were analyzed for their contribution to data assessment, documentation, decision support, and pharmacovigilance activities. Challenges related to data integrity, ethical responsibility, transparency, system validation, and differences in global regulatory expectations were also assessed. Artificial intelligence was found to significantly improve regulatory efficiency by enabling rapid data processing, structured documentation, and predictive regulatory analysis that reduces manual workload and strengthens decision accuracy. Regulatory authorities in multiple regions have begun adopting advanced digital frameworks that support standardized data exchange, collaborative review mechanisms, and more robust monitoring of drug safety. Despite these advancements, concerns remain regarding fairness of algorithms, reliability of automated outputs, protection of confidential information, and the absence of unified international standards. Artificial intelligence technologies provide strong opportunities to streamline regulatory pathways, improve the consistency and reliability of regulatory decisions, and support broader global harmonization. Successful implementation requires proactive attention to ethical, technical, and regulatory challenges to ensure transparent, responsible, and effective integration within pharmaceutical regulatory affairs.

27 February 2003 in Research Journal of Pharmacy and Technology
Verified
Journal Article
Closed access
PRPriyadharseni R.
Priyadharseni R.
DRDhinesh. R
Dhinesh. R
NSNagalakshmi S
Nagalakshmi S
This study aimed at fabricating a novel electrospun sandwich-structured polylactide–polyglycolide (PLGA)/collagen nanofibrous membranes. For the electrospinning of biodegradable membranes, PLGA/collagen and PLGA/ofloxacin were separately dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP). They were then electrospun into sandwich structured membranes, with PLGA/collagen for the surface layers and PLGA/OFL for the core layer. After electrospinning, various characterization studies were carried out for the prepared nanofibrous scaffold. The morphology of spun PLGA/collagen/OFL nanofibers was examined by scanning electron microscopy. The average diameter of electrospun nanofibers was 59 nm (range of 58–66 nm). The nature of the scaffold was determined by X-ray diffraction studies and rate of drug release was studied through in vitro activity. The experiment showed that biodegradable nanofibrous membranes released a sustainable concentration of drugs for a defined period of 8 hours. This would be a potential biomaterial in the field of corneal tissue engineering. The empirical results obtained from this study indicate that electrospun drug loaded sandwich PLGA/collagen nanofibers may be a good candidate for corneal damage.